CDK4 and neoplasm: Unlike most prior studies on CDK4/6 inhibitor resistance, which focused exclusively on tumor DNA, our study explored both the DNA landscape (via WES) and the transcriptomic landscape (via RNA-seq), using both tumor biopsies and ctDNA.